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Abstract 
Background: We evaluated the effects of 3-O-methyldopa (3-OMD), a metabolite of l-DOPA which is formed by 
catechol-O-methyltransferase (COMT), on the uptake, metabolism, and neuroprotective effects of l-DOPA in striatal 
astrocytes. We examined changes in the numbers of dopaminergic neurons after treatment with l-DOPA and 3-OMD 
or entacapone, a peripheral COMT inhibitor, using primary cultured mesencephalic neurons and striatal astrocytes.
Results: The number of tyrosine hydroxylase-positive dopaminergic neurons was not affected by l-DOPA treat-
ment in mesencephalic neurons alone. However, the increase in viability of dopaminergic neurons in the presence of 
astrocytes was further enhanced after methyl-l-DOPA treatment (25 µM) in mixed cultured mesencephalic neurons 
and striatal astrocytes. The neuroprotective effect of 25 µM l-DOPA was almost completely inhibited by simultaneous 
treatment with 3-OMD (10 or 100 µM), and was enhanced by concomitant treatment with entacapone (0.3 µM). The 
uptake of l-DOPA into and the release of glutathione from striatal astrocytes after l-DOPA treatment (100 µM) were 
inhibited by simultaneous exposure to 3-OMD (100 µM).
Conclusions: These data suggest that l-DOPA exerts its neuroprotective effect on dopaminergic neurons via 
astrocytes and that 3-OMD competes with l-DOPA by acting on target molecule(s) (possibly including glutathione) 
released from astrocytes. Since some amount of entacapone can cross the blood–brain barrier, this reagent may 
enhance l-DOPA transportation by inhibiting COMT and increase the astrocyte-mediated neuroprotective effects of 
l-DOPA on dopaminergic neurons.
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Background
Astrocytes are abundant neuron-supporting glial cells 
that harbor a powerful arsenal of neuroprotective anti-
oxidants and neurotrophic factors [1, 2]. However, astro-
cytes have not as yet been used as targets for clinical 
therapeutic drug development for the treatment of Par-
kinson’s disease (PD). We have previously revealed that 
some reagents targeting astrocytes have neuroprotec-
tive effects against dopaminergic neurodegeneration in 
Parkinson’s mouse models. These compounds enhanced 
astrocyte proliferation and upregulated the production 
of antioxidant molecules, such as glutathione (GSH) 
and metallothionein, in astrocytes [3, 4]. Furthermore, 
our recent study indicated that striatal astrocytes act as 
a reservoir for l-DOPA, which is the most widely used 
drug in patients with PD. Specifically, we observed that 
astrocytes uptake or release l-DOPA depending on 
extracellular l-DOPA concentrations without converting 
it to dopamine (DA) [5]. Although it is still unresolved 
whether l-DOPA is toxic to accelerate degeneration of 
DA neurons in PD patients, it is the most therapeuti-
cally efficacious drug for the treatment of PD to date [6]. 
l-DOPA has been shown to increase GSH levels, exert 
neurotrophic effects, and protect neurons from oxidative 
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stress in mesencephalic neuronal and glial mixed cul-
tures, but not in neurons alone [7, 8].
3-O-Methyldopa (3-OMD), a major metabolite of 
l-DOPA, is formed by catechol-O-methyltransferase 
(COMT) in peripheral tissues and in the brain [9]. It 
accumulates in the plasma and the brain because of its 
longer half-life (15  h) than l-DOPA (1  h) [10]. 3-OMD 
competitively inhibits l-DOPA transport into the brain at 
the blood–brain barrier [11, 12]. It also inhibits l-DOPA 
accumulation in the striatum by inhibiting aromatic 
amino acid decarboxylase activity, and not by inhibiting 
the firing of dopaminergic neurons [13]. Furthermore, 
3-OMD inhibits DA release from rat striatal slices [14]. 
Thus, 3-OMD competitively inhibits the pharmacody-
namics of l-DOPA and dopamine.
In order to clarify whether 3-OMD affects astrocyte-
mediated effects of l-DOPA, we evaluated the uptake 
and metabolism of l-DOPA in striatal astrocytes, the 
release of GSH and neurotrophic factors from astrocytes, 
and the neuroprotective effects of l-DOPA mediated 
by striatal astrocytes. We used primary cultured mes-
encephalic neurons and striatal astrocytes treated with 
methyl-l-DOPA, a water-soluble form of l-DOPA which 
can be rapidly converted to l-DOPA in culture medium 
[5], and 3-OMD. We also examined the effects of entaca-
pone, a peripheral COMT inhibitor, on l-DOPA-induced 
changes in the numbers of dopaminergic neurons in a 
mixed culture of neurons and astrocytes.
Methods
Materials
Methyl-l-DOPA ester hydrochloride (methyl-l-DOPA, 
D1507) and 3-OMD monohydrate (3-methoxy-l-ty-
rosine, M4255) were purchased from Sigma-Aldrich 
(St. Louis, MO). Entacapone was obtained from Orion 
Pharma (Espoo, Finland).
Animals
All animal procedures described in our experiments 
were in strict accordance with the Guidelines for Animal 
Experiments of Okayama University Advanced Science 
Research Center, and were approved by the Animal Care 
and Use Committee of Okayama University Advanced 
Science Research Center. Special care was taken to mini-
mize the number of animals used. For primary striatal 
or mesencephalic cell cultures, pregnant Sprague–Daw-
ley rats were purchased from Charles River Japan, Inc. 
(Yokohama, Japan).
Cell culture
Primary striatal and mesencephalic cell cultures 
were prepared as described previously [15]. Briefly, 
we dissected striatal and mesencephalic tissue from 
Sprague–Dawley rat embryos at 15  days of gestation. 
After trypsin treatment, cells from the striatum or the 
mesencephalon were incubated with 0.004 % deoxyribo-
nuclease I and 0.03  % trypsin inhibitor (Sigma-Aldrich) 
at 37  °C for 7 min. After centrifugation (420g × 5 min), 
the cell pellet was gently resuspended in 4  ml of Dul-
becco’s Modified Eagle Medium (Gibco BRL, Rock-
ville, MD) supplemented with 10  % fetal bovine serum, 
4 mM l-glutamine, and 60 µg/ml kanamycin sulfate. The 
dissociated cells were plated onto six-well culture plates 
or four-chamber glass culture slides coated with poly-
d-lysine (Becton–Dickinson Labware, Bedford, MA) at a 
density of 2 × 105 cells/cm2. For mesencephalic neuron-
enriched cultures (mesencephalic neurons), we replaced 
the medium with fresh medium supplemented with 
2 µM cytosine-β-d-arabinofuranoside (Sigma-Aldrich) to 
inhibit the replication of non-neuronal cells 24 h after ini-
tial plating of the dissociated cells. We then incubated the 
cells for five more days. Preliminary studies confirmed 
that 95  % of the neuron-rich cultures were immunore-
active for the neuronal marker microtubule-associated 
protein 2. For striatal glial-enriched cell cultures (stri-
atal astrocytes), dissociated cells were incubated in the 
same culture medium for 7 days, then subcultured onto 
six-well culture plates (3.6  ×  104 cells/cm2) and incu-
bated for another 7, 2 and 7 days for the measurement of 
GSH, glial cell line derived neurotrophic factor (GDNF), 
and basic fibroblast growth factor (bFGF), respectively. 
Alternatively, we subcultured the astrocytes onto 100-
mm dishes (6.4  ×  104 cells/cm2) for the measurement 
of l-DOPA and DA, and incubated them for another 
14  days. Over 95  % of the cultured glial-enriched cells 
showed immunoreactivity to glial fibrillary acidic protein. 
For neuron-astrocyte cocultures, striatal astrocytes were 
seeded at a density of 2 ×  104 cells/cm2 directly onto a 
layer of mesencephalic neurons that were already cul-
tured in 4-chamber slides for 4  days, as described. The 
cell mixture was then cocultured for another 2 days. All 
cultures were maintained at 37  °C in a 5–95 % CO2–air 
gas mixture.
Treatments
Mesencephalic neurons or a mixed culture of mesence-
phalic neurons and striatal astrocytes on four-chamber 
culture slides were treated with methyl-l-DOPA (25 µM) 
and/or 3-OMD monohydrate (10 or 100  µM), or with 
methyl-l-DOPA (25  µM) and/or entacapone (0.03, 0.1, 
or 0.3  µM) for 24  h prior to immunohistochemistry for 
the detection of dopaminergic neurons. Striatal astro-
cytes grown on 6-well plates were treated with methyl-
l-DOPA (25 or 100 µM) and/or 3-OMD (10 or 100 µM) 
for 24 h and the concentrations of GSH in astrocytes and 
GSH released from astrocytes were measured. For the 
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measurement of GDNF and bFGF, astrocytes were cul-
tured on 6-well plates for 2 days for GDNF measurement 
or 7 days for bFGF measurement, and then treated with 
methyl-l-DOPA (25  µM for GDNF, 50  µM for bFGF) 
and/or 3-OMD (10 or 100  µM) in serum-free medium 
for 24  h. To measure the concentrations of l-DOPA, 
and DA and its metabolites in astrocytes, striatal astro-
cytes were treated with methyl-l-DOPA (100  µM) and/
or 3-OMD (10 µM) for 4 h. To measure the levels of GSH, 
GDNF, and bFGF released from astrocytes, we collected 
glia conditioned medium (GCM) after a 24-h treatment 
with methyl-l-DOPA and/or 3-OMD, centrifuged it at 
3000×g for 3  min to remove cellular debris, and stored 
the supernatant at −80 °C until use.
Immunohistochemistry
Cells on chamber slides were fixed with 4 % paraformal-
dehyde (Nakarai, Kyoto, Japan) for 20 min, washed with 
10  mM phosphate-buffered saline (PBS, pH 7.4), and 
blocked with 2.5  % normal goat serum (Vector Labora-
tories, Burlingame, CA) for 20 min at 23  °C. Cells were 
then incubated with rabbit anti-tyrosine hydroxylase 
(TH) antibody (1:1000 dilution, Protos Biotech Corpora-
tion, New York, NY) diluted in 10  mM PBS containing 
0.1  % Triton X-100 (0.1  % PBST) for 18  h at 4  °C. The 
secondary antibody was goat anti-rabbit IgG conjugated 
to Alexa Fluor 488 (1:200 dilution, Molecular Probes, 
Eugene, OR). The cells were counterstained with Hoechst 
nuclear stain (10 µg/ml, Molecular Probes) for 2 min and 
washed before mounting with Fluoromounting medium 
(Dako Cytomation, Glostrup, Denmark).
All slides were observed under a fluorescence micro-
scope (Olympus BX50-FLA, Tokyo, Japan) using a 
mercury lamp using a 470–490  nm or a 360–370  nm 
band-pass filter to excite Alexa Fluor 488 or Hoechst dye, 
respectively. Light emitted from Alexa Fluor 488 or Hoe-
chst dye was collected through a 515–550 nm band-pass 
filter or a 420  nm long-pass filter, respectively. Adobe 
Photoshop CS4 software (Adobe, Waltham, MA) was 
used for digital amplification of the images.
Determination of total GSH
GSH levels in cultured cells and GCM were determined 
by the enzymatic recycling method of Tietze [16] with 
some modifications [3]. To prepare the samples, homog-
enized cells in 0.1 M phosphate buffer (pH 7.4) or GCM 
were treated with equivalent volumes of 10 % trichloro-
acetic acid. After centrifugation, the acid extracts were 
mixed with 0.01  M phosphate buffer (pH 7.4, 174  µl), 
NADPH (4  mM, 15  µl), GSH reductase (6  U/ml, 30  µl, 
Wako Pure Chemical, Tokyo, Japan) and 5,5′-dithiobis-
2-nitrobenzoic acid (10 mM, 15 µl, Wako), and incubated 
at 37  °C. The formation of 2-nitro-5-thiobenzoic acid 
was measured by absorbance at 412 nm. Total GSH was 
determined using a standard curve that was constructed 
using known amounts of GSH.
Measurements of GDNF and bFGF
The levels of GDNF and bFGF released from astrocytes 
in serum-free GCM were measured by enzyme-linked 
immunosorbent assay (ELISA) using a GDNF Emax 
Immunoassay System (Promega, Madison, WI, USA) and 
an ELISA kit for Rat Fibroblast Growth Factor 2, Basic 
(FGF2) (Uscn Life Science Inc., Wuhan, China) accord-
ing to the manufacturer’s protocols. Aprotinin (10 µg/ml) 
and leupeptin (1 µg/ml) were added to serum-free GCM 
collected from methyl-l-DOPA and/or 3-OMD-treated 
striatal astrocytes.
The GDNF in GCM was captured by monoclonal anti-
GDNF antibody precoated onto a 96-well plate and col-
orimetrically detected using a polyclonal anti-GDNF 
antibody, horseradish peroxidase (HRP)-conjugated 
anti-IgY, and the chromogenic substrate 3,3′,5,5′-tetra-
methylbenzidine (TMB). The concentration of GDNF 
was quantified by measuring the absorbance at 450  nm 
and comparing to a GDNF standard. bFGF in GCM and 
biotin-labeled bFGF were competitively captured by the 
monoclonal anti-bFGF antibody precoated on a well and 
the bound biotinylated bFGF was detected via its sub-
sequent reaction with avidin-conjugated HRP and the 
chromogen TMB. As before, the absorbance was meas-
ured at 450 nm. The concentration of bFGF in GCM was 
determined using a reverse proportional standard curve.
Measurement of intracellular l‑DOPA, and DA and its 
metabolites
The contents of l-DOPA, and DA and its metabolites, 
3-OMD, 3,4-dihydroxyphenyl acetic acid (DOPAC) and 
homovanillic acid (HVA), were measured in astrocytes 
treated with methyl-l-DOPA and/or 3-OMD using 
high-performance liquid chromatography with an elec-
trochemical detector (HPLC-ECD), as described previ-
ously [5]. Striatal astrocytes treated with methyl-l-DOPA 
(100 µM) and/or 3-OMD (10 µM) for 4 h were homog-
enized using 5 volumes of 200  mM ice-cold perchloric 
acid containing 10  mM ethylenediaminetetraacetic acid 
(EDTA, Dojindo, Kumamoto, Japan). After centrifugation 
(11,750×g, 20 min at 4  °C), the supernatant was filtered 
(0.45 µm) and then injected directly into an HPLC-ECD 
(Tosoh Co., Tokyo). The HPLC system consisted of a 
delivery pump (PX-8020, Tosoh Co.) and an analyti-
cal column (EICOMPAK SC-5ODS, 3.0 mm × 150 mm, 
Eicom Co., Kyoto, Japan). An electrochemical detector 
(EC-8020, Tosoh Co.) with glassy carbon at a voltage set-
ting of 700 mV and an Ag/AgCl reference electrode were 
used. A mobile phase containing 0.1  M citrate-sodium 
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acetate buffer (pH 3.5), methanol (17 % v/v), EDTA-2Na, 
and sodium 1-octanesulfonate was infused at a flow rate 
of 0.6  ml/min. Regarding the detection limit, the peak 
less than 3  mV/min was not detected. Extraction effi-
ciency was approximate 25 % by measuring internal con-
trol isoproterenol which was put into cell preparation 
before homogenization.
Statistical analysis
Results are presented as mean  ±  standard error of the 
mean (SEM). Between-group differences were analyzed 
by one-way analysis of variance (ANOVA), followed by 
post hoc Fisher’s PLSD test. A p value less than 0.05 indi-
cated the presence of a statistically significant difference.
Results
Striatal astrocyte‑mediated effects of l‑DOPA and 3‑OMD 
on mesencephalic dopaminergic neurons
Primary cultured mesencephalic neurons alone are vul-
nerable, with gradually decreasing cell numbers dur-
ing cultivation. Treatment with 3-OMD (10 or 100 µM) 
enhanced this vulnerability and significantly decreased 
the numbers of mesencephalic DA neurons (Fig. 1a). In 
mesencephalic neurons alone, methyl-l-DOPA (25 µM), 
with or without 3-OMD (10 or 100  µM) showed no 
effects on the number of TH-positive DA neurons 
(Fig. 1b). The viability of DA neurons is increased by the 
presence of astrocytes [17]. In mesencephalic neurons 
co-cultured with striatal astrocytes, methyl-l-DOPA 
(25 µM) further increased the viability of mesencephalic 
TH-positive dopaminergic neurons (Fig.  1c). Neither 
methyl-l-DOPA nor 3-OMD affected total number of 
neurons (data not shown). The neuroprotective effect of 
methyl-l-DOPA (25  µM) in mixed cultures was almost 
completely inhibited by concomitant treatment with 
3-OMD (10 or 100  µM) for 24  h (Fig.  1c). We recently 
revealed that striatal astrocytes act as a reservoir of 
l-DOPA and govern the uptake or release of l-DOPA 
depending on extracellular l-DOPA concentrations 
[5]. Therefore, we examined the effects of 3-OMD on 
l-DOPA uptake and metabolism into/in striatal astro-
cytes. We observed marked increases in the concentra-
tion of l-DOPA and 3-OMD in striatal astrocytes after a 
4-h methyl-l-DOPA (100 µM) treatment (Table 1). In the 
present study, l-DOPA was not converted to DA and its 
metabolites DOPAC and HVA in astrocytes as previously 
reported [5]. Furthermore, we performed measurement 
of l-DOPA, DA and its metabolites using other HPLC-
ECD system (EICOM 300, Eicom Co., Kyoto). However, 
we again failed to detect DA and its metabolites DOPAC 
and HVA in astrocytes (data not shown). The failure of 
detecting DA and its metabolites indicates that aromatic 
amino acid decarboxylase (AADC) appears inactive in 
the astrocytes [5]. The exposure to 3-OMD (10  µM) 
increased its level in the astrocytes. Simultaneous expo-
sure to 10 µM 3-OMD significantly inhibited the uptake 
of l-DOPA into astrocytes, but showed just additive 
effects on the level of 3-OMD in the astrocytes (Table 1).
Effects of l‑DOPA and 3‑OMD on GSH or its release in/from 
striatal astrocytes
The neuroprotective effects of l-DOPA on mesence-
phalic DA neurons are dependent on the presence of 
striatal astrocytes. It has been reported that l-DOPA 
increases GSH levels to protect neurons against oxidative 
stress in neuron-astrocyte mixed cultures [7, 8], and that 
GSH synthesis in neurons is dependent on GSH synthesis 
in astrocytes and its release [18, 19]. To investigate pos-
sible factors involved in the astrocyte-mediated neuro-
protective effects of l-DOPA, we examined changes in 
the levels of GSH in astrocytes and its release from astro-
cytes after methyl-l-DOPA and/or 3-OMD treatment. 
Exposure to 3-OMD had no effects on GSH levels in stri-
atal astrocytes (Fig. 2a). Treatment with 100 µM methyl-
l-DOPA for 24 h, and to a lesser extent at the lower dose 
25  µM, significantly decreased GSH contents in astro-
cytes (Fig.  2b) and increased GSH levels in the GCM, 
indicating the release of GSH from astrocytes (Fig.  2c). 
This l-DOPA (100 µM)-induced GSH release from stri-
atal astrocytes was counteracted by concomitant treat-
ment with 100 µM 3-OMD (Fig. 2b, c). We also measured 
GDNF and bFGF released from astrocytes into the 
GCM following treatment with methyl-l-DOPA and/or 
3-OMD. Treatment with 25 µM methyl-l-DOPA for 24 h 
increased the levels of GDNF in the GCM. This increase 
was not affected by simultaneous exposure to 3-OMD 
(Additional file 1: Fig. S1A). Neither lower (25 µM: data 
not shown) and higher (50 µM) doses of methyl-l-DOPA 
nor 3-OMD affected the levels of bFGF in the GCM 
(Additional file 1: Fig. S1B).
Effects of entacapone on l‑DOPA‑induced striatal 
astrocyte‑mediated neuroprotection
The conversion of l-DOPA to 3-OMD is inhibited by 
the peripheral COMT inhibitor entacapone. Since small 
amounts of entacapone can cross the blood–brain bar-
rier, we examined whether entacapone can enhance the 
astrocyte-mediated neuroprotective effects of l-DOPA 
in the present study. As well as the results in Fig.  1c, 
the treatment with 25  µM methyl-l-DOPA for 24  h 
increased the number of TH-positive dopaminergic neu-
rons in mixed cultures of mesencephalic neurons and 
striatal astrocytes (Fig.  3a–c). Concomitant treatment 
with entacapone enhanced l-DOPA-induced increases in 
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the numbers of dopaminergic neurons in a dose-depend-
ent manner, especially when used at 0.3  µM (Fig.  3c). 
The single entacapone treatment showed no effects on 
the number of TH-positive neurons in primary cultured 
mesencephalic neurons alone in the absence of astrocytes 
(data not shown).
Discussion
In the present study, we examined the effects of the 
l-DOPA metabolite 3-OMD, which is formed by COMT, 
and the peripheral COMT inhibitor entacapone on the 
astrocytic uptake, metabolism, and neuroprotective 
effects of l-DOPA. The main findings of this study are: (1) 
Fig. 1 Changes in the number of TH-positive cells in primary cultured mesencephalic neurons (a, b) or in mixed cultured mesencephalic neurons 
with striatal astrocytes (c) after the treatment with 3-OMD (10, 100 µM) alone (a) or methyl-l-DOPA (25 µM) and 3-OMD (10, 100 µM) (b, c) for 24 h. 
Each value is mean ± SEM of total number of TH-positive neurons from different 4 chambers (n = 4), which is expressed as percentage of control. 
*p < 0.05, **p < 0.01 versus vehicle-treated control, ###p < 0.001 versus methyl-l-DOPA-treated group
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methyl-l-DOPA treatment (25 µM) increases the viability 
of DA neurons in mixed cultures of mesencephalic neu-
rons and striatal astrocytes, but not in mesencephalic neu-
rons alone, (2) the neuroprotective effects of l-DOPA on 
mesencephalic DA neurons are inhibited by simultaneous 
treatment with 3-OMD, (3) increased l-DOPA uptake into 
astrocytes and the GSH release from striatal astrocytes 
after methyl-l-DOPA treatment are significantly inhibited 
by simultaneous exposure to 3-OMD, and (4) the neuro-
protective effects of l-DOPA in the presence of astrocytes 
are enhanced by concomitant treatment with entacapone.
Mesencephalic neurons, especially TH-positive DA 
neurons, are vulnerable to oxidative stress. The viabil-
ity of primary cultured DA neurons gradually decreases 
when they are cultivated in the absence of astrocytes. 
However, the vulnerability of DA neurons is amelio-
rated by the presence of astrocytes [17]. In the present 
study, l-DOPA treatment (25 µM) increased the viabil-
ity of DA neurons co-cultured with striatal astrocytes, 
suggesting that the neuroprotective effects of l-DOPA 
are exerted via astrocytes. We recently demonstrated 
that striatal astrocytes act as regulators of extracellular 
l-DOPA concentrations by their uptake or release of 
l-DOPA [5]. It is well known that 3-OMD competitively 
inhibits the pharmacodynamics of l-DOPA at various 
points, including its transport at the blood–brain bar-
rier and its uptake into and release from neurons [11, 
12, 14]. Also, in the present study, 3-OMD inhibited 
l-DOPA uptake into astrocytes, but showed no effect 
on the intracellular metabolism of l-DOPA in striatal 
astrocytes. Our results indicate that 3-OMD also coun-
teracted the effects of l-DOPA in astrocytes. Specifi-
cally, it inhibited the uptake of l-DOPA into astrocytes 
and reduced the astrocyte-mediated neuroprotective 
effects of l-DOPA.
The neurotoxic effects of 3-OMD was not in a dose-
dependent manner (Fig.  1a). This implies that DA neu-
rons have an intrinsic protective mechanism against 
3-OMD, which is independent of astrocytes. Another 
possible mechanism is that up-taking of 3-OMD is satu-
rated by low dose of 3-OMD. These may cause small pro-
tective effects of presence of astrocytes.
Treatment with proper doses of l-DOPA has been 
reported to protect neurons against oxidative stress 
through the up-regulation of GSH production in neuron-
astrocyte mixed cultures [7, 8], although excess doses of 
l-DOPA have been shown to be neurotoxic [2, 20]. In 
the present study, the optimal dose of l-DOPA signifi-
cantly increased the viability of DA neurons (Figs. 1, 3), 
while excess dose of l-DOPA rather declined the num-
ber of DA neurons in the neuron-astrocyte mixed cul-
tures (data not shown). It is known that GSH synthesis 
in neurons is dependent on its synthesis in and release 
from astrocytes [18, 19]. Previous reports suggest that 
l-DOPA-induced astrocytic GSH synthesis and release 
are possible key neuroprotective events. We therefore 
examined astrocytic GSH contents and the release off 
GSH from astrocytes following methyl-l-DOPA and/
or 3-OMD treatment. l-DOPA treatment promoted 
GSH release from striatal astrocytes, which was inhib-
ited by simultaneous exposure to 3-OMD. In the control 
and lower dose l-DOPA-treated groups, total amount 
of GSH, that is intracellular level (Fig.  2b) plus released 
extracellular level of GSH (Fig. 2c), is constant. However, 
higher dose of l-DOPA (100 µM) increased total amount 
of GSH, suggesting l-DOPA promoted GSH synthesis as 
well as GSH release. We also measured the levels of the 
neurotrophic factors GDNF and bFGF released from 
astrocytes. The release of GDNF from astrocytes was 
enhanced by l-DOPA treatment, but was not affected by 
3-OMD. These data suggest that l-DOPA exerts its neu-
roprotective effects on DA neurons via astrocytes and 
that 3-OMD competes with l-DOPA by acting on target 
molecule(s)—possibly including GSH, but not GDNF or 
bFGF—released from astrocytes.
The COMT-catalyzed production of 3-OMD from 
l-DOPA is inhibited by peripheral COMT inhibitors 
such as entacapone and tolcapone, which hardly cross 
the blood–brain barrier. However, small amount of 
peripherally administered entacapone are transported 
into the brain and distributed into the striatum (approxi-
mately 0.2 % of plasma concentration) [21], although the 
penetration of entacapone into brain tissue is less than 
that of tolcapone. We therefore expected that the entaca-
pone reaching the brain would inhibit 3-OMD formation 
and enhance the astrocyte-mediated neuroprotective 
effects of l-DOPA. As expected, concomitant treatment 
with low concentrations of entacapone (0.03–0.3  µM) 
Table 1 Concentration of  l-DOPA, dopamine and  their 
metabolites in striatal astrocytes 4 h after methyl-l-DOPA 
(100 µM) and/or 3-OMD (10 µM) exposure
Striatal astrocytes were treated with methyl-l-DOPA (100 µM) and/or 3-OMD 
(10 µM) for 4 h. The concentrations of l-DOPA, DA, DOPAC, HVA and 3-OMD 
were measured by HPLC assay. N.D: not detected. Data (pmol/mg protein) are 
presented as mean ± SEM (n = 4)
 * p < 0.05, ** p < 0.001 versus control group
 ## p < 0.001 versus methyl-l-DOPA-treated group
$$ p < 0.001 versus 3-OMD-treated group
Control 3‑OMD Methyl‑l‑DOPA 3‑OMD + methyl‑
l‑DOPA
l-DOPA N.D. N.D. 411.0 ± 12.1** 347.0 ± 15.6**,##
DA N.D. N.D. N.D. N.D.
DOPAC N.D. N.D. N.D. N.D.
HVA N.D. N.D. N.D. N.D.
3-OMD N.D. 12.5 ± 1.02** 15.3 ± 1.57** 26.0 ± 0.83**,##,$$
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enhanced the l-DOPA (25 µM)-induced increases in the 
numbers of DA neurons in a dose-dependent manner. 
This effect was especially prominent at the 0.3 µM dose. 
This suggests that entacapone may enhance l-DOPA 
transportation not only by inhibiting 3-OMD formation, 
but also by altering the astrocyte-mediated neuroprotec-
tive effects of l-DOPA on DA neurons.
Conclusion
Here we report that l-DOPA treatment increases 
l-DOPA uptake by striatal astrocytes and astrocytic 
GSH release and exerts its neuroprotective effect on 
DA neurons in the presence of astrocytes. Furthermore, 
the astrocyte-mediated effects of l-DOPA were coun-
teracted by concomitant treatment with 3-OMD and 
Fig. 2 GSH levels in striatal astrocytes (a, b) or in their GCM (c) after the treatment with 3-OMD (10 or 100 µM) alone (a) or methyl-l-DOPA (25 or 
100 µM) and 3-OMD (10 or 100 µM) (b, c) for 24 h. Data are mean ± SEM (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001 versus control vehicle-treated, 
##p < 0.01 versus methyl-l-DOPA-treated group
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enhanced by entacapone treatment. 3-OMD exposure 
inhibited astrocytic l-DOPA uptake and GSH release. 
Taken together, the present data suggest that 3-OMD 
competes with l-DOPA by acting on target molecule(s) 
(possibly including GSH) released from astrocytes. Since 
small amounts of entacapone, which promotes l-DOPA 
transport by inhibiting COMT, can cross the blood–
brain barrier, it may enhance the astrocyte-mediated 
Fig. 3 Effects of entacapone on methyl-l-DOPA (25 µM)-induced changes in the number of TH-positive cells in mixed primary cultured mesence-
phalic neurons with striatal astrocytes. Mixed neurons and astrocytes were treated with methyl-l-DOPA (25 µM) and entacapone (0.03, 0.1 or 0.3 µM: 
a, b or c, respectively) for 24 h. Values are mean of the number of TH-positive cells ± SEM (n = 4 chambers) expressed as percentage of control. 
*p < 0.05, **p < 0.01 versus vehicle-treated control, #p < 0.05 versus methyl-l-DOPA-treated group, $p < 0.05, $$p < 0.01 versus entacapone-treated 
group
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neuroprotective effects of l-DOPA on DA neurons. Fur-
ther in vivo examination is needed to confirm the neuro-
protective effects of l-DOPA and entacapone.
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